ProCE Banner Activity

Updated Results of a Phase I/IIa Trial of CLN-081, a Selective EGFR TKI, in Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations

Slideset Download
Conference Coverage
Manageable safety and promising antitumor activity observed with CLN-081 in patients with previously treated advanced NSCLC harboring EGFR exon 20 insertion mutations.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab